Atrial fibrillation (AFib) is the most common cardiac arrhythmia worldwide and a major contributor to heart failure (HF), ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced. The glucagon-like peptide-1 ...

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become ...

A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

A new 2026 study reveals how chronic stress depletes NAD⁺, impairing immunity and accelerating liver cancer—while linking the ...

Your face serves as a remarkable window into your overall health, often revealing internal problems long before you experience obvious symptoms. When it comes to fatty liver disease, one of the most ...

A large population-based study has found that older adults with atrial fibrillation who also have metabolic dysfunction-associated steatotic liver disease face a significantly higher risk of ...